Stargardt Disease (and Fundus Flavimaculatus)

Author(s):  
Mohsin H. Ali ◽  
Lejla Vajzovic
Retina ◽  
2004 ◽  
Vol 24 (6) ◽  
pp. 920-928 ◽  
Author(s):  
KEAN T. OH ◽  
RICHARD G. WELEBER ◽  
EDWIN M. STONE ◽  
DAWN M. OH ◽  
JUSTIN ROSENOW ◽  
...  

2021 ◽  
Vol 62 (14) ◽  
pp. 24
Author(s):  
Julien Fars ◽  
Francesca Pasutto ◽  
Jan Kremers ◽  
Cord Huchzermeyer

2008 ◽  
Vol 18 (2) ◽  
pp. 239-247 ◽  
Author(s):  
G. Querques ◽  
R. Prato ◽  
C. Iaculli ◽  
M. Voigt ◽  
N. Delle Noci ◽  
...  

Purpose To investigate the relationship between morphologic lesions of the retina and functional abnormalities in patients with Stargardt disease (STGD) and fundus flavimaculatus (FFM). DESIGN. Case-controlled, prospective, comparative observational study. Methods A complete ophthalmologic examination, including best-corrected visual acuity (BCVA) and optical coherence tomography (OCT), was performed in 61 eyes of 32 consecutive patients with STGD/FFM and in 60 eyes of 30 matched healthy control subjects. Furthermore, fundus-related perimetry was performed in 12 of the affected eyes. Results The age ranged from 21 to 71 years in STGD/FFM patients and from 21 to 72 years in controls. BCVA ranged from 20/20 to 20/400 and from 20/20 to 20/32, respectively, in STGD/FFM patients and in controls. A foveal thinning was found by OCT Stratus in almost all cases (average 160 μm) compared with controls (average 210 μm) (pp<0.001). BCVA impairment significantly correlated to the degree of foveal thinning (r2=0.16; p=0.0014). Moreover, in STGD/FFM patients the authors observed two types of hyperreflective deposits which were not correlated with BCVA impairment or foveal thinning. In addition, fundus-related perimetry revealed a stable fixation in 8/12 eyes, that was predominantly central in only 4 of these eyes. A smaller degree of foveal thinning correlated to a more stable fixation (p=0.0108), even if not predominantly central (p=0.0218). Conclusions In this series, lower visual acuity and unstable fixation correlated with a greater transverse foveal thinning. OCT and fundus-related perimetry may be useful tools in STGD/FFM patients.


Stargardt macular dystrophy is a hereditary retinal degeneration that lacks effective treatment options. The pathophysiology of the disease is still not fully understood. While there are currently no available treatments for Stargardt disease, there are many categories of therapeutics under investigation to fulfill this unmet need for treatment. These include investigational visual cycle modulators, complement inhibitors, ABCA4 gene therapy, and subretinal transplantation of stem cell-derived retina pigment epithelial cells. Further trials are warranted to assess efficacy and safety in humans. In this review, the treatments investigated for the Stargardt disease are explained.


2021 ◽  
Vol 1 (1) ◽  
pp. 100005
Author(s):  
Rachael C. Heath Jeffery ◽  
Jennifer A. Thompson ◽  
Johnny Lo ◽  
Tina M. Lamey ◽  
Terri L. McLaren ◽  
...  

2021 ◽  
pp. 100259
Author(s):  
Jin Zhao ◽  
Hye Jin Kim ◽  
Keiko Ueda ◽  
Kevin Zhang ◽  
Diego Montenegro ◽  
...  

Genes ◽  
2019 ◽  
Vol 10 (6) ◽  
pp. 452 ◽  
Author(s):  
Alejandro Garanto ◽  
Lonneke Duijkers ◽  
Tomasz Z. Tomkiewicz ◽  
Rob W. J. Collin

Deep-sequencing of the ABCA4 locus has revealed that ~10% of autosomal recessive Stargardt disease (STGD1) cases are caused by deep-intronic mutations. One of the most recurrent deep-intronic variants in the Belgian and Dutch STGD1 population is the c.4539+2001G>A mutation. This variant introduces a 345-nt pseudoexon to the ABCA4 mRNA transcript in a retina-specific manner. Antisense oligonucleotides (AONs) are short sequences of RNA that can modulate splicing. In this work, we designed 26 different AONs to perform a thorough screening to identify the most effective AONs to correct splicing defects associated with c.4539+2001G>A. All AONs were tested in patient-derived induced pluripotent stem cells (iPSCs) that were differentiated to photoreceptor precursor cells (PPCs). AON efficacy was assessed through RNA analysis and was based on correction efficacy, and AONs were grouped and their properties assessed. We (a) identified nine AONs with significant correction efficacies (>50%), (b) confirmed that a single nucleotide mismatch was sufficient to significantly decrease AON efficacy, and (c) found potential correlations between efficacy and some of the parameters analyzed. Overall, our results show that AON-based splicing modulation holds great potential for treating Stargardt disease caused by splicing defects in ABCA4.


Sign in / Sign up

Export Citation Format

Share Document